News
News
2024
All
Development
Product Info
IR
Information
- 2024.08.23IR
- Notice Concerning Termination of Exclusive Sales Rights Agreements for HGF Gene Therapy Product "Collategene"
- 2024.07.29IR
- Notice Regarding the Recognition of Costs Associated with the Termination of Sales of the Products
- 2024.06.06IR
- Notice Concerning Supply Agreement for "Zokinvy"
- 2024.05.29IR
- Tie2 receptor agonist (AV-001), co-development product, received fast track designation from the U.S. FDA
- 2024.05.15IR
- Notice of AnGes, Inc. to Pledge Financial Support for SLDDDRS at Stanford University School of Medicine
- 2024.05.08IR
- Notice Regarding the Decision to Sell the Zokinvy Business of Eiger BioPharmaceuticals, Inc.
- 2024.04.17IR
- Notice on the NHI Drug Price Standard Listing and Launch Schedule of Zokinvy for the Treatment of Progeria
- 2024.04.16Information
- Vasomune Selected to Present on AV-001 Development Status at American Thoracic Society
- 2024.04.12IR
- Notice Regarding Eiger BioPharmaceuticals, Inc.
- 2024.03.14IR
- Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for FY2024
- 2024.02.22IR
- FY2023 Financial Results Materials （correction）
2023
All
Development
Product Info
IR
Information
- 2023.08.07Information
- Our subsidiary, Emendobio Inc., has been selected as the Best Startup of the Prix Galien USA Award, the Nobel Prize in the pharmaceutical field
- 2023.04.24IR
- Notice Concerning Acquisition and Cancellation of the 42nd Series of Stock Acquisition Rights
- 2023.03.08Information
- NOTICE OF THE 24TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
- 2023.02.16IR
- FY2022 Financial Results Materials
2022
All
Development
Product Info
IR
Information
- 2022.12.26IR
- Notice of Investment in Vasomune Therapeutics Inc.
- 2022.11.10IR
- Notice Concerning Conclusion of Joint Research and Development Agreement with BioSafety Research Center Inc.
- 2022.10.07Information
- Introduction of AnGes 2022
- 2022.09.26IR
- Notice of Issuance of 42nd Series of Stock Acquisition Rights (Third Party Allotment of Moving Strike Warrants)
- 2022.09.16IR
- About the September 7, 2022 Announcements
- 2022.06.16IR
- Notice Regarding Posting of Non-operating Income
2021
All
Development
Product Info
IR
Information
- 2021.11.05IR
- Novel Coronavirus (COVID-19) DNA Vaccine: Results of Phase 1/2 and Phase 2/3 Clinical Trials
2020
All
Development
Product Info
IR
Information
- 2020.12.18IR
- Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment
- 2020.11.13IR
- FDA Allowance of IND Application For AV-001 for the Treatment of Hospitalized Patients with COVID-19
- 2020.10.08IR
- AnGes and Er-Kim enter into an agreement for the commercialization of Collategene® in Turkey
- 2020.09.08IR
- COVID-19 DNA vaccine development_Announcement of Collaboration Agreement with Brickell Biotech
- 2020.04.14IR
- COVID-19 DNA vaccine project : Peptite Institute joins for the peptide synthesis research
- 2020.04.10IR
- COVID-19 DNA vaccine project : Listed on the COVID-19 candidate vaccines in WHO (World Health Organization)
- 2020.04.07IR
- COVID-19 DNA vaccine project: Participation of EPS Group to support the clinical trials
- 2020.03.24IR
- COVID-19 DNA vaccine project: Completion of Plasmid DNA vaccine for preclinical studies
- 2020.03.13IR
- COVID-19 DNA vaccine project:Participation of Daicel corporation with a new administration device technology
2019
All
Development
Product Info
IR
Information
- 2019.09.04Product Info
- Notice regarding the launch of Collategene® intramuscular injection 4 mg, an HGF gene therapy product
- 2019.03.26Product Info
- AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia
- 2019.02.22IR
- Notice of Convocation Annual General Meeting 2019
2018
All
Development
Product Info
IR
Information
- 2018.04.12Development
- AnGes Announces First Patient Treated with DNA Vaccine for Hypertension in Phase I / II Clinical Study in Australia
- 2018.02.27Development
- AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain
- 2018.02.23IR
- Notice of Convocation Annual General Meeting 2018
- 2018.02.02IR
- Consolidated Financial Report for 2017
2017
All
Development
Product Info
IR
Information
- 2017.04.25Development
- AnGes Announces FDA Clearance of Investigational New Drug (IND) Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain
- 2017.03.24Development
- Investigational New Drug (IND) Application Submitted to the FDA Initiating a clinical trial with NF-kappaB decoy for the treatment of discogenic lower back pain
- 2017.03.02IR
- Notice of Convocation Annual General Meeting 2017
- 2017.02.20IR
- Announcement Regarding Decrease in the Amount of Stated Capital and Capital Reserve and Appropriation of Surplus
- 2017.02.20IR
- Notice Concerning Change of Trade Name
- 2017.02.03IR
- Consolidated Financial Report for 2016
2016
All
Development
Product Info
IR
Information
- 2016.08.01IR
- AnGes Announces Investment in Vical
- 2016.07.12Development
- AnGes to Start Development of Next-Generation Decoy Oligonucleotide --Fundamental Technologies Established for STAT 6/NF-kB Chimera Decoy as a Treatment for Inflammatory Diseases--
- 2016.07.05Development
- AnGes Announces Top-Line Results for Japanese Phase III Clinical Trial of NF-κB Decoy Oligonucleotide for Atopic Dermatitis
- 2016.06.20Development
- AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia
- 2016.04.26Development
- AnGes Collaborates with University of Saskatchewan’s VIDO-InterVac to Develop Ebola Polyclonal Antibody Therapy Using DNA Vaccine Technology
2015
All
Development
Product Info
IR
Information
- 2015.09.07Development
- Last Patient Out in Clinical Trial of the NF-κB Decoy Oligo Coated PTA Balloon Catheter for Hemodialysis Shunts
- 2015.08.12Development
- Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia
- 2015.06.15Development
- Increase in Titers of Antibodies against Ebola Glycoprotein Confirmed in Initial Equine Study for Ebola Polyclonal Antibody Therapy Using DNA Vaccine Technology
- 2015.06.05Information
- AnGes will attend the 2015 BIO International Convention on June 15th-18th in Philadelphia, PA
- 2015.06.05Development
- AnGes’s gene medicine development featured in Nature Biopharma Dealmakers June 2015 Issue
- 2015.05.25IR
- Cancellation of Share Issuance Program
- 2015.03.16Development
- AnGes Starts Phase III Clinical Trials of NF-kB Decoy Oligonucleotide Ointment Drug for Atopic Dermatitis in Japan
2014
All
Development
Product Info
IR
Information
- 2014.12.24Development
- AnGes to Develop Disc Degeneration Drug Using NF-kB Decoy Nucleotide in the US
- 2014.11.16Development
- First Patient Dosed in Global Phase III Clinical Trials of HGF Plasmid for Critical Limb Ischemia
- 2014.10.29Development
- AnGes to Start Global Phase III Clinical Trials of HGF Gene Therapy for Critical Limb Ischemia in Europe
- 2014.10.16Development
- First Patient Dosed in Physician-led Study of HGF Gene Therapy in Japan
- 2014.10.06Development
- AnGes Starts Global Phase III Clinical Trials of Collategene® for Critical Limb Ischemia
- 2014.05.30Development
- Announcement Regarding CollategeneⓇ Project in Japan
- 2014.05.15IR
- CollategeneⓇ (DNA Plasmid with HGF Gene) Lymphedema Project Selected for NEDO’s Venture Aid Program
- 2014.05.02Development
- AnGes Amends Development Strategy of NF-kB Decoy Oligonucleotide for Atopic Dermatitis Treatment Drug
- 2014.03.26IR
- Allocation of New Shares to Third Party (Summary)
- 2014.03.20Development
- AnGes Commences Small Scale Clinical Study of CollategeneⓇ for Critical Limb Ischemia
2013
All
Development
Product Info
IR
Information
- 2013.11.22Development
- Completion of IRB Review for the Small-scale Study of CollategeneⓇ
- 2013.11.19Development
- Vical Announces Results of a Phase 3 Trial of Allovectin® at the International Meeting of the Society for Melanoma Research
- 2013.10.28IR
- For Investors/IR Library: Consolidated Financial Report for the 9 Months Ended September 30, 2013
- 2013.10.16Development
- Pre-clinical Study Results of Collategene® (HGF Gene Drug Treatment) for Lymphedema Published in a Medical Journal
- 2013.10.04Development
- Phase 1/2 Study of CollategeneⓇ (HGF Gene Therapy) Starts in Japan – The World’s First Gene Therapy for Lymphedema –
- 2013.10.01IR
- Summary of the Announcement Regarding the Issue of Stock Acquisition Rights to UBS AG London Branch
- 2013.09.25Development
- New Medical-use Patent for HGF Gene Therapy Granted in Japan - Combination Therapy with PGIS Gene Enhances Angiogenic Effect -
- 2013.09.17Development
- AnGes, Inc. Submits the Protocol for Small-scale Study of CollategeneⓇ for IRB Review
- 2013.08.27IR
- CIN Therapeutic Vaccine Research Project to Receive Health and Labour Sciences Research Grant
- 2013.08.19Development
- Resumption of Development of Collategene® in Japan
- 2013.08.16IR
- The Current Situation of AnGes
- 2013.08.13Development
- Background to the Report of Vical’s Phase 3 Trial Results of Allovectin®
- 2013.08.12Development
- Results of Vical’s Phase III Trial of Allovectin®
- 2013.08.02IR
- For Investors/IR Library: Consolidated Financial Report for 6 Months Ended June 30, 2013
- 2013.07.30IR
- AnGes and Tella Sign Basic Agreement for Joint Research and Development of CIN Therapeutic Vaccine
- 2013.07.24Development
- Completion of NIH RAC Review for the Protocol of Small-scale Study of CollategeneⓇ
- 2013.06.27Development
- AnGes Inc. Submits the Protocol of Small-scale Study of CollategeneⓇ to NIH’s RAC Review
- 2013.06.24Development
- Phase I Study Starts for NF-κB Decoy Oligo Atopic Dermatitis Treatment Drug
- 2013.05.23Development
- AnGes submits an IND application for small-scale clinical study of CollategeneⓇ in the United States (US)
- 2013.05.10IR
- For Investors/IR Library: Consolidated Financial Report for the 3 Months Ended M
- 2013.05.07IR
- NEDO Adopts Lymphedema Project of CollategeneⓇ (DNA Plasmid with HGF Gene) as its Venture Aid Program
- 2013.04.23Development
- Enhancing Effect of Japanese Herbal Medicine on CIN Therapeutic Vaccine
- 2013.04.17Development
- AnGes and Shionogi Agree to Start a Phase I Study for Atopic Dermatitis Treatment Drug
- 2013.04.11IR
- For Investors/IR Library: Consolidated Financial Report for the Year Ended December 31, 2012
- 2013.03.18Development
- The Efficacy and Safety of Oral CIN Therapeutic Vaccine reconfirmed in an Investigator-initiated Clinical Study (STEP 2)
2012
All
Development
Product Info
IR
Information
- 2012.11.19Information
- AnGes Receives an Award at Society of Cerebral-Cardio-Vascular Anti-Aging 2012 for the Development of Functional Peptide with Anti-aging effects and Antimicrobial Activity
- 2012.11.16Development
- New Research Findings on Functional Peptide “COSMEPEPTINR” Reported at Society of Cerebral-Cardio-Vascular Anti-Aging 2012
- 2012.10.29IR
- For Investors/IR Library: Consolidated Financial Report for the Nine Months Ended September 30, 2012
- 2012.10.01Development
- New Medical Use Patent for HGF Granted in Japan for Lymphedema
- 2012.08.03IR
- For Investors/IR Library: Consolidated Financial Report for 6 Months Ended June 30, 2012
- 2012.07.30Development
- AnGes MG Submits an IND Application for Collategene (HGF DNA Plasmid) - Initiation of the World’s First Clinical Trial on Gene Therapy for Lymphedema -
- 2012.05.21Information
- Introduction of Shareholder Special Benefit Plan
- 2012.05.16Development
- Collaboration with Morishita Jintan regarding New Formulation Development for Oral Vaccines using Seamless Capsule Technology
- 2012.05.08IR
- For Investors/IR Library: Consolidated Financial Report for the 3 Months Ended March 31, 2012
- 2012.04.11Development
- Medical-Use Patent for NF-kB Decoy Oligo Granted in Japan
2011
All
Development
Product Info
IR
Information
- 2011.12.02Information
- Research Finding Report on and Academic Society Award for Functional Peptide, “COSMEPEPTIN (TM)” - Findings on COSMEPEPTIN (TM) reported at Anti-Aging Festa 2011; Anti-Aging Medicine Practices -
- 2011.09.26Information
- Second Prize in the Year 2011 Intellectual Property Award by Osaka Prefecture - HGF (Hepatocyte Growth Factor) Gene Therapy against Peripheral Arterial Obstruction -
- 2011.09.22Development
- The Developmental Status of Anticancer Drug, HVJ-E (GEN0101/TSD-0014) by GenomIdea, a Subsidiary of AnGes MG
- 2011.09.12Development
- Completion of RAC Review by NIH - Protocol for U.S. Phase III Clinical Trial on “Collategene(TM),” Therapeutic Agent for Ischemic Disease -
- 2011.08.10Development
- Co-Development of Novel Cosmetic and Healthcare Products, Using Functional Peptides - A Basic Agreement with St. Louis International, Inc. Concluded -
- 2011.08.09Development
- Medical-Use Patent for Ets-1 Granted in the U.S. - Intended for Angiogenesis/Gene Therapy Using Transcription Factor, Ets-1 -
- 2011.08.08IR
- New Appointment of Corporate Officer
- 2011.08.08Development
- GenoLac BL Co. and AnGes MG, Inc. Concluded a Basic Agreement - Joint Development of Therapeutic Vaccines for HPV -
- 2011.06.16Development
- GenomIdea, a Subsidiary of AnGes MG, and TSD Japan Sign Contract for Joint Conduct of Licensing Activities - Strengthen Licensing Activities toward Global Development of GEN0101/TSD-0014 -
- 2011.06.13Development
- Medical-Use Patent for GEN0101/TSD-0014 (HVJ-E) Granted in Japan - Intended for Anti-Cancer Drugs -
- 2011.05.24Development
- Substance Patent for NF-κB/E2F Chimera Decoy-Oligonucleotide Granted in Europe - Covering new type decoy oligodeoxynucleotides which can inhibit multiple transcription factors -
- 2011.03.24Development
- Medical Journal Publication of Results of Study on Collategene (HGF gene therapy product) in Japan - Data of Open-Label Study Targeting Buerger’s Disease -
- 2011.03.15Information
- Notices Regarding the Effects of the Tohoku Earthquake and Tsunami
- 2011.03.02Development
- New Medical-Use Patent for HGF Gene Therapy Granted in Japan - For Treatment or Prophylaxis of Brain Infarction -
- 2011.02.16Information
- AnGes MG’s Founder Receives the “Japan Venture Awards 2011” - Awarded for excellency in the founding of venture businesses and management -
- 2011.02.09Development
- Medical-Use Patent for HGF Gene Granted in Japan - Covering the combination use of hyperbaric oxygen therapy with angiogenesis factor gene therapy in order to improve therapeutic effects -
- 2011.01.11Development
- Medical Journal Publication of Data of US Phase II Study of Collategene (HGF plasmid)
2010
All
Development
Product Info
IR
Information
- 2010.12.31IR
- Consolidated Financial Report for the Year Ended
- 2010.12.27IR
- Shionogi Co., Ltd. and AnGes Agree on Co-Development of NF-kB Decoy for Atopic Dermatitis
- 2010.12.24Development
- Pharmaceutical Formulation Patent on NF-κB Decoy-Oligonucleotide Granted in Japan and US - Covering PLGA particle preparations with enhanced penetration to the site of treatment -
- 2010.12.02Development
- Report on Long-Term Data of Collategene (HGF plasmid) - Japanese Phase III Study for CLI -
- 2010.10.20Development
- Development of Novel Disinfectant Utilizing Antimicrobial Peptide "Cure-Peptin"through Joint R＆D Efforts with Morishita Jintan Co., Ltd.
- 2010.10.12Development
- Success in Developing Improved Decoys Suitable for Intravenous Infusion - Publication in Medical Journal -
- 2010.09.29Development
- Basic Patent for HVJ-E Granted in the US - Covering Exogenous Gene Transfer Methods -
- 2010.09.17Product Info
- AnGes-MG to conduct an additional clinical trial for Collategene(TM),HGF Plasmid for Ischemic Disease Treatment
- 2010.09.17Development
- Investigation of Collategene(TM), HGF Plasmid for Ischemic Disease Treatment designated as the Fast Track development program by the FDA
- 2010.09.17IR
- Revised Full-Year Business Forecasts
- 2010.08.09Development
- alphaGEN and AnGes MG Reaches Basic Agreement on Joint Research Aiming to Develop New Nucleic Acid Medicine “siRNA”
- 2010.08.02Development
- New Medical Use Patent for HGF Gene Granted in USA - Targeting Parkinson’s Disease -
- 2010.07.29IR
- EPS and AnGes Concluded a Comprehensive Business Alliance Aiming to Explore for Business Expansion in China
- 2010.06.30Development
- Published Paper Reporting the Results from Collategene Phase III Clinical Trial Performed in Japan Receives the Research Achievement Award of the Asian Society for Vascular Surgery
- 2010.06.14Development
- Patentability for Broad Spectrum of NF-κB Decoy Oligo Approved in USA - Covering Medical Use of Broader Spectrum of Decoy Sequences -
- 2010.04.21Development
- Medical Journal Publication of Data from "Collategene" Phase III Clinical Study Performed in Japan
- 2010.03.25Development
- New Medical-Use Patent for HGF Gene Granted in Japan - Covering Parkinson’s Disease -
- 2010.02.24Development
- A Medical Use Patent Granted in Japan for Angiogenesis Targeting a New Gene, Endothelial Nitric Oxide Synthase (eNOS)
- 2010.02.04Development
- Announcement about the Progress of Allovectin-7(R) Phase III Trial
2009
All
Development
Product Info
IR
Information
- 2009.11.24Development
- Agreement on SPA with the US FDA for Phase III Clinical Trial for CollategeneTM, a Drug for Ischemic Disease Treatment
- 2009.11.24Development
- Product Patent on Dumbbell-Type (Ribbon-Type) E2F Decoy Oligonucleotide Granted in Japan --- Covering a Circular Oligonucleotide Sequence ---
- 2009.10.22Development
- Patent on New Decoy Oligonucleotide Granted in Japan —Covering NF-κB/ets chimera (double) decoy—
- 2009.07.29Development
- Medical-Use Patent on NF-κB Decoy Oligonucleotide Granted in Japan - Covering Psoriasis -
- 2009.04.27Development
- Joint R＆D with Morishita Jintan Co., Ltd.-Development of New Products Based on Functional Peptides with Antimicrobial Activity-
- 2009.04.15Development
- Substance Patent on Dumbbell-Type (Ribbon-Type) NF-κB Decoy Oligonucleotide Granted in Japan -Covering a Circular Oligonucleotide Sequence-
- 2009.03.26IR
- AnGes Project Adopted to Receive NEDO Support - Development of Novel Disinfectants with Antibacterial Peptides -
- 2009.03.02Development
- AnGes Reached a Broad Agreement with the FDA on the Clinical Trial Designs for Their Phase III Study with Collategene™
- 2009.02.16Development
- Announcement about the progress of Allovectin-7® Phase 3 pivotal trial
2008
All
Development
Product Info
IR
Information
- 2008.12.10Development
- Announcement of New Developments Concerning the Manufacturing of Novel Nucleic-Acid Hybrid Decoy
- 2008.11.12Development
- New Direction in the Development of NF-κB Decoy Oligodeoxynucleotide for the Treatment of Atopic Dermatitis in Japan
- 2008.10.28Development
- Therapeutic Effects of GEN0101 on Hormone-Refractory Prostate Cancer Confirmed - Announcement of Results of Animal Studies at the 67th Japanese Cancer Association General Meeting-
- 2008.10.24IR
- Amendments of the License Agreement between Meyer Pharmaceuticals LLC and AnGes MG, Inc.
- 2008.10.23Development
- Announcement of Results of Phase IIa Clinical Trials of STAT-1 Decoy Oligodeoxynucleotide on Psoriasis in Europe
- 2008.10.02Development
- New Medical Use Patent Granted in Europe - Covering Severe Diabetic Peripheral Artery Occlusive Diseases -
- 2008.10.01Development
- Substance Patent for a NF-κB Decoy-Oligonucleotide Granted in Japan - Covering AnGes MG’s Decoy Sequence Currently Under Development -
- 2008.09.30Development
- Announcement of Industrial/Academic Four-Party Joint R＆D Project on Novel Nucleic Acid Hybrid Decoy for the Treatment of Intractable Inflammatory Diseases
- 2008.08.06Development
- A Medical Use Patent Granted in Europe for Angiogenesis Targeting a New Gene, Endothelial Nitric Oxide Synthase (eNOS)
- 2008.07.08Development
- New Medical-Use Patent for HGF Gene Therapy Granted in USA - Covering Treatment and Prophylaxis of Auditory Dysfunction -
- 2008.07.02Development
- New Medical Use Patent for HGF Granted in Japan - Covering the Treatment of Lymphedema -
- 2008.05.26Development
- Medical Use Patent for the Combination Use of HGF and PGIS Granted in Europe - Covering Angiogenic Therapy -
- 2008.05.15Development
- New Medical-Use Patent for HGF Gene Granted in Europe - Covering Cardiomyopathy -
- 2008.04.14Product Info
- AnGes MG, Inc. Launched Naglazyme in Japan
- 2008.04.07Development
- Medical Use Patent on NF-κB Decoy-Oligo Granted in Europe - Covering Its Use for Atopic Dermatitis
- 2008.03.28Product Info
- AnGes Submits NDA for HGF Gene Therapy
- 2008.03.28Product Info
- AnGes MG, Inc. Receives Approval for Manufacturing and Marketing of Naglazyme
- 2008.02.25Product Info
- Status Updates of NDA application of Naglazyme for the Treatment of Mucopolysaccharidosis VI
2007
All
Development
Product Info
IR
Information
- 2007.11.15
- Announcement of Joint R＆D Contract Termination between Goodman Co., Ltd. and AnGes MG, Inc.
2006
All
Development
Product Info
IR
Information
- 2006.05.26
- Results of Phase I Clinical Trials of NFκB Decoy Oligo in the Treatment of Atopic Dermatitis
- 2006.05.08
- Results of the US Phase I Clinical Trials with HGF Gene Plasmid for Ischemic Heart Disease (IHD)
2005
All
Development
Product Info
IR
Information
2004
All
Development
Product Info
IR
Information
- 2004.11.09IR
- AnGes MG Joins Hands with ImmunoFrontier -- Transfer of Patent Rights for Cancer DNA Vaccine --
- 2004.09.01Information
- Announcement: Relocation of Headquarters and Research Center -- Integration of Headquarters and Research Center to Saito --
- 2004.07.26Development
- GenomIdea’s Joint Development with Mitsubishi Space Software Bears Fruit -- Development of a New Drug Design System for the Next-generation Nucleic acid Medicine "siRNA" Completed --
- 2004.03.17IR
- AnGes MG Expanding Its US Presence -Licensing activities now in full-swing on the bioventure-rich US West Coast-
- 2004.03.17Development
- Commencement of Clinical trials for HGF Genetic Medicine in Japan -The first multi-centered double-blind trial for genetic medicine in Japan-
- 2004.02.20IR
- AnGes MG appoints new director
2003
All
Development
Product Info
IR
Information
- 2003.12.08Development
- Japanese medical-use patent issued for NFB decoy oligo -Covering treatment and preventive drugs for ischemic diseases, organ transplantions and cancers -
- 2003.07.28Development
- Key Japanese patent issued covering HGF gene therapy
- 2003.05.01Development
- Clinical trials underway for HGF genetic medicine in the United States
- 2003.03.24Development
- Notification of joint genetic function analysis R＆D
- 2003.02.20IR
- Notice on the Granting of Stock Options
- 2003.02.20IR
- Personnel Changes at AnGes MG
- 2003.02.10IR
- Key Personnel Change at AnGes MG
- 2003.01.08Development
- IND application approved for HGF genetic medicine treating peripheral arterial diseases
2002
All
Development
Product Info
IR
Information
- 2002.12.02Development
- Investigational New Drug (IND) application filed with the USFDA for HGF genetic medicine
- 2002.11.21Development
- Notice on the Completion of the Pilot Plant for Manufacturing HVJ Envelope Vectors
- 2002.10.16IR
- Placing new shares with third parties
- 2002.10.10Information
- Announcement regarding some newspaper reports
- 2002.10.07Information
- Announcement regarding some newspaper reports
- 2002.09.25Information
- Representative Director and Vice President
2001
All
Development
Product Info
IR
Information